{"id":400627,"date":"2020-12-16T04:34:56","date_gmt":"2020-12-16T09:34:56","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=400627"},"modified":"2020-12-16T04:34:56","modified_gmt":"2020-12-16T09:34:56","slug":"arecor-announces-publication-of-phase-i-data-for-at247-in-diabetes-care","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/arecor-announces-publication-of-phase-i-data-for-at247-in-diabetes-care\/","title":{"rendered":"Arecor Announces Publication of Phase I Data for AT247 in Diabetes Care"},"content":{"rendered":"

\nAT247, a promising candidate in the pursuit for next generation insulins to improve glycemic control
\n<\/h2>\n
\n

CAMBRIDGE, United Kingdom, Dec. 16, 2020 (GLOBE NEWSWIRE) — Arecor Limited\u00a0(“Arecor” or “the Company”),<\/em>\u00a0the biopharmaceutical company advancing today’s therapies to enable healthier lives,\u00a0today announces that\u00a0Diabetes Care<\/em>\u00a0has published data for the Phase I clinical trial of AT247, its ultra-rapid acting insulin product candidate.<\/p>\n

The manuscript titled\u00a0‘Pharmacokinetics and Pharmacodynamics of Three Different Formulations of Insulin Aspart: A Randomized, Double blind, Crossover Study in Men with Type 1 Diabetes’ is available online from today via\u00a0https:\/\/care.diabetesjournals.org\/lookup\/doi\/10.2337\/dc20-1017<\/u><\/a>. \u00a0<\/p>\n

In the Phase I clinical study, AT247 exhibited an earlier insulin appearance, exposure, and offset, with corresponding enhanced early glucose-lowering effect compared with both NovoRapid\u00ae<\/sup>\u00a0and Fiasp\u00ae<\/sup>. \u00a0\u00a0\u00a0<\/p>\n

AT247, a novel formulation of insulin, aims to accelerate insulin absorption, post injection, to enable more effective management of blood glucose levels.\u00a0 AT247 has the potential to significantly improve post prandial glucose control so avoiding episodes of both hypo and hyperglycemia.<\/p>\n

\n Dr Eva Svehlikova, first author of the study, said:<\/strong>\u00a0“Publication of these data in a peer-reviewed journal supports\u00a0the representation of AT247 as a promising candidate in the pursuit for next generation ultra-rapid acting insulin designed to improve postprandial glycemic control and flexibility of dosing.\u00a0 This early evidence suggests that AT247 may also facilitate a fully closed loop artificial pancreas, a potentially life changing treatment option for people living with diabetes.”\u00a0<\/p>\n

Please click on the below link to view the full announcement.
http:\/\/www.rns-pdf.londonstockexchange.com\/rns\/7609I_1-2020-12-15.pdf<\/a><\/p>\n

\n For more information, please contact:<\/strong>\n <\/p>\n\n\n\n\n\n\n\n\n
\n Arecor Limited<\/strong>\n <\/td>\n\n
\n www.arecor.com<\/u>
\n <\/a>\n <\/td>\n<\/tr>\n
Dr Sarah Howell, Chief Executive Officer<\/td>\nTel: +44 (0) 1223 426060
Email:\u00a0info@arecor.com<\/u><\/a><\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Susan Lowther, Chief Financial Officer<\/td>\nTel: +44 (0) 1223 426060
Email:\u00a0info@arecor.com<\/u><\/a><\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n Mo PR Advisory<\/strong>\n <\/td>\n\n
\n www.mopradvisory.com<\/u>
\n <\/a>\n <\/td>\n<\/tr>\n
Mo Noonan<\/td>\nMob: +44 (0) 7876 444977
Email:\u00a0mo@mopradvisory.com<\/u><\/a>\u00a0<\/td>\n<\/tr>\n<\/table>\n

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\u00a0rns@lseg.com<\/a>\u00a0or visit\u00a0www.rns.com<\/a>.<\/p>\n

\u00a0<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

AT247, a promising candidate in the pursuit for next generation insulins to improve glycemic control CAMBRIDGE, United Kingdom, Dec. 16, 2020 (GLOBE NEWSWIRE) — Arecor Limited\u00a0(“Arecor” or “the Company”),\u00a0the biopharmaceutical company advancing today’s therapies to enable healthier lives,\u00a0today announces that\u00a0Diabetes Care\u00a0has published data for the Phase I clinical trial of AT247, its ultra-rapid acting insulin product candidate. The manuscript titled\u00a0‘Pharmacokinetics and Pharmacodynamics of Three Different Formulations of Insulin Aspart: A Randomized, Double blind, Crossover Study in Men with Type 1 Diabetes’ is available online from today via\u00a0https:\/\/care.diabetesjournals.org\/lookup\/doi\/10.2337\/dc20-1017. \u00a0 In the Phase I clinical study, AT247 exhibited an earlier insulin appearance, exposure, and offset, with corresponding enhanced early glucose-lowering effect compared with both NovoRapid\u00ae\u00a0and Fiasp\u00ae. \u00a0\u00a0\u00a0 AT247, a novel formulation of … <\/p>\n

Continue reading “Arecor Announces Publication of Phase I Data for AT247 in Diabetes Care”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-400627","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nArecor Announces Publication of Phase I Data for AT247 in Diabetes Care - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/arecor-announces-publication-of-phase-i-data-for-at247-in-diabetes-care\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Arecor Announces Publication of Phase I Data for AT247 in Diabetes Care - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"AT247, a promising candidate in the pursuit for next generation insulins to improve glycemic control CAMBRIDGE, United Kingdom, Dec. 16, 2020 (GLOBE NEWSWIRE) — Arecor Limited\u00a0(“Arecor” or “the Company”),\u00a0the biopharmaceutical company advancing today’s therapies to enable healthier lives,\u00a0today announces that\u00a0Diabetes Care\u00a0has published data for the Phase I clinical trial of AT247, its ultra-rapid acting insulin product candidate. The manuscript titled\u00a0‘Pharmacokinetics and Pharmacodynamics of Three Different Formulations of Insulin Aspart: A Randomized, Double blind, Crossover Study in Men with Type 1 Diabetes’ is available online from today via\u00a0https:\/\/care.diabetesjournals.org\/lookup\/doi\/10.2337\/dc20-1017. \u00a0 In the Phase I clinical study, AT247 exhibited an earlier insulin appearance, exposure, and offset, with corresponding enhanced early glucose-lowering effect compared with both NovoRapid\u00ae\u00a0and Fiasp\u00ae. \u00a0\u00a0\u00a0 AT247, a novel formulation of … Continue reading "Arecor Announces Publication of Phase I Data for AT247 in Diabetes Care"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/arecor-announces-publication-of-phase-i-data-for-at247-in-diabetes-care\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-16T09:34:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMzIxMyMzODg0Mjg3IzUwMDA2OTY0Nw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arecor-announces-publication-of-phase-i-data-for-at247-in-diabetes-care\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arecor-announces-publication-of-phase-i-data-for-at247-in-diabetes-care\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Arecor Announces Publication of Phase I Data for AT247 in Diabetes Care\",\"datePublished\":\"2020-12-16T09:34:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arecor-announces-publication-of-phase-i-data-for-at247-in-diabetes-care\\\/\"},\"wordCount\":362,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arecor-announces-publication-of-phase-i-data-for-at247-in-diabetes-care\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMzIxMyMzODg0Mjg3IzUwMDA2OTY0Nw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arecor-announces-publication-of-phase-i-data-for-at247-in-diabetes-care\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arecor-announces-publication-of-phase-i-data-for-at247-in-diabetes-care\\\/\",\"name\":\"Arecor Announces Publication of Phase I Data for AT247 in Diabetes Care - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arecor-announces-publication-of-phase-i-data-for-at247-in-diabetes-care\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arecor-announces-publication-of-phase-i-data-for-at247-in-diabetes-care\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMzIxMyMzODg0Mjg3IzUwMDA2OTY0Nw==\",\"datePublished\":\"2020-12-16T09:34:56+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arecor-announces-publication-of-phase-i-data-for-at247-in-diabetes-care\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arecor-announces-publication-of-phase-i-data-for-at247-in-diabetes-care\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arecor-announces-publication-of-phase-i-data-for-at247-in-diabetes-care\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMzIxMyMzODg0Mjg3IzUwMDA2OTY0Nw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMzIxMyMzODg0Mjg3IzUwMDA2OTY0Nw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arecor-announces-publication-of-phase-i-data-for-at247-in-diabetes-care\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Arecor Announces Publication of Phase I Data for AT247 in Diabetes Care\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Arecor Announces Publication of Phase I Data for AT247 in Diabetes Care - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/arecor-announces-publication-of-phase-i-data-for-at247-in-diabetes-care\/","og_locale":"en_US","og_type":"article","og_title":"Arecor Announces Publication of Phase I Data for AT247 in Diabetes Care - Market Newsdesk","og_description":"AT247, a promising candidate in the pursuit for next generation insulins to improve glycemic control CAMBRIDGE, United Kingdom, Dec. 16, 2020 (GLOBE NEWSWIRE) — Arecor Limited\u00a0(“Arecor” or “the Company”),\u00a0the biopharmaceutical company advancing today’s therapies to enable healthier lives,\u00a0today announces that\u00a0Diabetes Care\u00a0has published data for the Phase I clinical trial of AT247, its ultra-rapid acting insulin product candidate. The manuscript titled\u00a0‘Pharmacokinetics and Pharmacodynamics of Three Different Formulations of Insulin Aspart: A Randomized, Double blind, Crossover Study in Men with Type 1 Diabetes’ is available online from today via\u00a0https:\/\/care.diabetesjournals.org\/lookup\/doi\/10.2337\/dc20-1017. \u00a0 In the Phase I clinical study, AT247 exhibited an earlier insulin appearance, exposure, and offset, with corresponding enhanced early glucose-lowering effect compared with both NovoRapid\u00ae\u00a0and Fiasp\u00ae. \u00a0\u00a0\u00a0 AT247, a novel formulation of … Continue reading \"Arecor Announces Publication of Phase I Data for AT247 in Diabetes Care\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/arecor-announces-publication-of-phase-i-data-for-at247-in-diabetes-care\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-16T09:34:56+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMzIxMyMzODg0Mjg3IzUwMDA2OTY0Nw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arecor-announces-publication-of-phase-i-data-for-at247-in-diabetes-care\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arecor-announces-publication-of-phase-i-data-for-at247-in-diabetes-care\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Arecor Announces Publication of Phase I Data for AT247 in Diabetes Care","datePublished":"2020-12-16T09:34:56+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arecor-announces-publication-of-phase-i-data-for-at247-in-diabetes-care\/"},"wordCount":362,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arecor-announces-publication-of-phase-i-data-for-at247-in-diabetes-care\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMzIxMyMzODg0Mjg3IzUwMDA2OTY0Nw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arecor-announces-publication-of-phase-i-data-for-at247-in-diabetes-care\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/arecor-announces-publication-of-phase-i-data-for-at247-in-diabetes-care\/","name":"Arecor Announces Publication of Phase I Data for AT247 in Diabetes Care - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arecor-announces-publication-of-phase-i-data-for-at247-in-diabetes-care\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arecor-announces-publication-of-phase-i-data-for-at247-in-diabetes-care\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMzIxMyMzODg0Mjg3IzUwMDA2OTY0Nw==","datePublished":"2020-12-16T09:34:56+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arecor-announces-publication-of-phase-i-data-for-at247-in-diabetes-care\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/arecor-announces-publication-of-phase-i-data-for-at247-in-diabetes-care\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arecor-announces-publication-of-phase-i-data-for-at247-in-diabetes-care\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMzIxMyMzODg0Mjg3IzUwMDA2OTY0Nw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMzIxMyMzODg0Mjg3IzUwMDA2OTY0Nw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arecor-announces-publication-of-phase-i-data-for-at247-in-diabetes-care\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Arecor Announces Publication of Phase I Data for AT247 in Diabetes Care"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/400627","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=400627"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/400627\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=400627"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=400627"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=400627"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}